HOLM; Rene

Patent Applications and Registrations

Patent applications and USPTO patent grants for HOLM; Rene.The latest application filed is for "pharmaceutical formulations".

Company Profile

4.11.16

HOLM; Rene - Woluwe Saint Pierre BE
Holm; Rene - Jyllinge DK

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Pharmaceutical Formulations App 20220175760 - KIMPE; Kristof Leonard ; et al.	2022-06-09
Vortioxetine pyroglutamate Grant 11,279,682 - de Diego , et al. March 22, 2	2022-03-22
1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine As A Compound With Combined Serotonin Reuptake, 5-ht3 And 5-ht1a Activity Fo App 20200163959 - Faldt; Andre ; et al.	2020-05-28
Formulations/compositions Comprising Ibrutinib App 20190381174 - Bernini; Maristella ; et al.	2019-12-19
Vortioxetine Pyroglutamate App 20190210987 - de Diego; Heidi Lopez ; et al.	2019-07-11
Vortioxetine pyroglutamate Grant 10,287,261 - de Diego , et al.	2019-05-14
1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine As A Compound With Combined Serotonin Reuptake, 5-ht3 And 5-ht1a Activity For The Treatment Of Cognitive Impairment App 20180333408 - Faldt; Andre ; et al.	2018-11-22
1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment Grant 9,861,630 - Faldt , et al. January 9, 2	2018-01-09
1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND With COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT App 20170360777 - Faldt; Andre ; et al.	2017-12-21
Method of administration of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia Grant 9,610,287 - Holm , et al. April 4, 2	2017-04-04
Vortioxetine Pyroglutamate App 20160368884 - de Diego; Heidi Lopez ; et al.	2016-12-22
1-[2-(2,4-DIMETHYLPHENYLSULFANYL)-PHENYL]PIPERAZINE AS A COMPOUND With COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT App 20160083359 - Bang-Andersen; Benny ; et al.	2016-03-24
1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment Grant 9,227,946 - Faldt , et al. January 5, 2	2016-01-05
1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment Grant 9,125,909 - Bang-Andersen , et al. September 8, 2	2015-09-08
1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT.sub.3 and 5-HT.sub.1A activity for the treatment of cognitive impairment Grant 9,125,908 - Bang-Andersen , et al. September 8, 2	2015-09-08
1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment Grant 8,969,355 - Bang-Andersen , et al. March 3, 2	2015-03-03
1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment App 20140315921 - Bang-Andersen; Benny ; et al.	2014-10-23
Method of administration of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia App 20140194409 - Holm; Rene ; et al.	2014-07-10
1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment Grant 8,722,684 - Bang-Andersen , et al. May 13, 2	2014-05-13
Method for treating cognitive deficits App 20110207744 - Olsen; Christina Kurre ; et al.	2011-08-25
Oral Formulation App 20110178094 - Holm; Rene ; et al.	2011-07-21
1- [2- (2,4-dimethylphenylsulfanyl)-phenyl] Piperazine As A Compound With Combined Serotonin Reuptake, 5-ht3 And 5-ht1a Activity For The Treatment Of Cognitive Impairment App 20100297240 - Bang-Andersen; Benny ; et al.	2010-11-25
Method For Treating Cognitive Deficits App 20090306092 - Olsen; Christina Kurre ; et al.	2009-12-10
Modified Absorption Formulation Of Gaboxadol App 20090143335 - Larsen; Mie ; et al.	2009-06-04

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.